2A Biosciences Inc. has divulged compounds acting as 5-HT2A and 5-HT2C receptor agonists reported to be useful for the treatment of atopic dermatitis, conjunctivitis, Crohn’s disease, type 2 diabetes, ...
Shionogi & Co. Ltd. has synthesized spiroheterocycle derivatives acting as 5-HT2A and 5-HT2C receptor antagonists and/or inverse agonists reported to be useful for the treatment of neurodegeneration.
Bright Minds Biosciences' BMB-101, a 5-HT2C receptor agonist, shows promise in treating drug-resistant epilepsy, with favorable Phase 1 safety and efficacy data. The company's proprietary platform ...
Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...
Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist.
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
SAN FRANCISCO (MarketWatch) -- Arena Pharmaceuticals Inc. said after Tuesday's closing bell it has been issued a U.S. patent for 5-HT2C receptor modulators. The patent relates to novel compounds that ...
Please provide your email address to receive an email when new articles are posted on . A clinical-stage biopharmaceutical company has announced positive topline data from a study evaluating a novel, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results